| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ABHD6 |
| Uniprot No | Q9BV23 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-337aa |
| 氨基酸序列 | MDLDVVNMFVIAGGTLAIPILAFVASFLLWPSALIRIYYWYWRRTLGMQV RYVHHEDYQFCYSFRGRPGHKPSILMLHGFSAHKDMWLSVVKFLPKNLHL VCVDMPGHEGTTRSSLDDLSIDGQVKRIHQFVECLKLNKKPFHLVGTSMG GQVAGVYAAYYPSDVSSLCLVCPAGLQYSTDNQFVQRLKELQGSAAVEKI PLIPSTPEEMSEMLQLCSYVRFKVPQQILQGLVDVRIPHNNFYRKLFLEI VSEKSRYSLHQNMDKIKVPTQIIWGKQDQVLDVSGADMLAKSIANCQVEL LENCGHSVVMERPRKTAKLIIDFLASVHNTDNNKKLD |
| 预测分子量 | 65 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ABHD6重组蛋白的3篇参考文献示例(注：文献信息为模拟生成，仅供参考)：
---
1. **文献名称**：**"Recombinant expression and functional characterization of human ABHD6 reveals its role as a key regulator of 2-arachidonoylglycerol hydrolysis"**
**作者**：Marrs, W.R. et al.
**摘要**：该研究在昆虫细胞系统中成功表达并纯化了重组人源ABHD6蛋白，通过体外酶活实验证实其特异性水解内源性大麻素2-AG(2-花生四烯酸甘油酯)的能力，并发现选择性抑制剂WWL70可显著抑制其活性，提示ABHD6是内源性大麻素代谢的关键调控靶点。
2. **文献名称**：**"Structural insights into the catalytic mechanism of ABHD6 through X-ray crystallography"**
**作者**：Li, X. et al.
**摘要**：本研究利用大肠杆菌表达系统制备了重组ABHD6蛋白，并通过X射线晶体学解析其高分辨率三维结构。结构分析揭示了ABHD6活性口袋的关键氨基酸残基，为基于结构的抑制剂设计提供了理论依据，同时验证了其与脂质底物的结合模式。
3. **文献名称**：**"ABHD6 knockdown exacerbates neuronal inflammation via elevation of 2-AG levels: Studies in recombinant protein-based cellular models"**
**作者**：Navia-Paldanius, D. et al.
**摘要**：通过哺乳动物细胞表达重组ABHD6蛋白，研究其在神经细胞模型中对2-AG代谢的调控作用。结果表明，ABHD6活性缺失导致2-AG水平升高，加剧神经炎症反应，提示其在神经退行性疾病中的潜在治疗价值。
---
**提示**：实际文献检索建议通过PubMed或Google Scholar使用关键词“ABHD6 recombinant protein”、“ABHD6 expression and purification”进行查询，并优先选择近五年内发表的论文以获取最新进展。
ABHD6 (α/β-hydrolase domain-containing protein 6) is a serine hydrolase belonging to the endocannabinoid system, primarily known for its role in hydrolyzing 2-arachidonoylglycerol (2-AG), a key endogenous cannabinoid ligand. It regulates endocannabinoid signaling by controlling 2-AG levels, influencing synaptic plasticity, neuroinflammation, and energy metabolism. ABHD6 is expressed in multiple tissues, including the brain, liver, and adipose tissue, and its dysregulation has been linked to neurological disorders (e.g., epilepsy, neuropathic pain) and metabolic syndromes (e.g., obesity, diabetes).
Recombinant ABHD6 protein is produced via heterologous expression systems (e.g., E. coli, mammalian cells) for functional and structural studies. Its recombinant form retains enzymatic activity, enabling researchers to study substrate specificity, inhibitor screening, and interaction networks. Purification often involves affinity tags (e.g., His-tag) followed by chromatography, ensuring high purity and stability.
Research on recombinant ABHD6 has accelerated drug discovery, particularly for inhibitors targeting its hydrolase activity. Such inhibitors may modulate endocannabinoid tone without systemic side effects, offering therapeutic potential for neurodegenerative diseases or metabolic dysregulation. Additionally, structural analyses of recombinant ABHD6 have revealed insights into its catalytic mechanism and substrate-binding pockets, guiding rational drug design.
Overall, ABHD6 recombinant protein serves as a critical tool for deciphering its physiological roles, validating drug candidates, and exploring its multifaceted impact on human health and disease.
×
